Collegium Pharmaceutical, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • COLL
  • 1d-1.60%
  • 1w-9.41%
  • 1m-10.10%
  • 1y53.25%
ATH
  • ATH Price$40.91
  • ATH Date2024-03-27
  • % since ATH-14.10%
  • % to ATH16.42%
ATL
  • ATL Price$7.59
  • ATL Date2017-05-08
  • % from ATL362.98%
  • Last Low Price$35.14
  • Last Low Date2024-04-15
  • % From Last Low0%
IPO
  • IPO Price$12.00
  • % Current ROI USD292.83%
  • ATH Price$40.91
  • % ROI ATH 53,899.87%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="COLL"]

Key Data [addtoany]

Current price $35.14
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Today's High/Low $35.83/$35.12
Volume 366,266.00
Previous Close $35.71
52 Week High/Low $40.95/$20.83
Market Cap 1,167,920,512.00
P/E Ratio 27.6822
Forward P/E 1 Yr. $5.78
Earnings Per Share(EPS) $3.67
Annualized Dividend $0
$35.14
[addtoany]

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Annual Data | Millions of US $ except per share data 2019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Cash on hand $170.02$146.63$118.70$153.23$95.70--
Receivables $72.95$77.95$9.97$2.13-$2.34-
Inventory $9.64$7.82$1.81$1.32$0$1.32-
Pre-Paid Expenses -------
Other Current Assets $0.14$1.01$0.46$0.30$0.56$0.53$0.71
Total Current Assets $255.72$237.51$133.48$158.58$96.88$4.50-
Property, Plant, And Equipment $20.90$9.27$1.83$1.04$0.74$0.51$0.69
Long-Term Investments -------
Goodwill And Intangible Assets --$0$0$0--
Other Long-Term Assets $0.18$0.20$0.26$0.30$0.10$0.08$0.08
Total Long-Term Assets $50.58$53.73$2.08$3.44---
Total Assets $306.30$291.25$135.57$162.02$97.72$5.09$9.03
Total Current Liabilities $201.77$189.13$31.49$25.60$8.43$10.42$2.62
Long Term Debt $7.67$9.86$0$1.48$4.15$6.81$0.64
Other Non-Current Liabilities -$0.68-$0.03$0.07$0.10$0.19
Total Long Term Liabilities $17.11$10.53$0$1.51---
Total Liabilities $218.87$199.66$31.49$27.11$12.65$17.33$3.45
Common Stock Net $0.03$0.03$0.03$0.03$0.02$0100000$0100000
Retained Earnings (Accumulated Deficit) $-359.90$-337.18$-298.05$-223.18$-129800000$-101.75-
Comprehensive Income --$0$0$0--
Other Share Holders Equity -------
Share Holder Equity $87.43$91.59$104.08$134.91$85.07$-89.35$5.58
Total Liabilities And Share Holders Equity -------